These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 29926514)

  • 21. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
    Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
    Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
    Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG
    BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study.
    Hövelmann U; Raiter Y; Chullikana A; Liu M; Donnelly C; Lawrence T; Sengupta N; Cl G; Ranganna G; Barve A
    Diabetes Obes Metab; 2021 Dec; 23(12):2670-2678. PubMed ID: 34378861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
    Sinn A; García-Alvarado F; Gonzalez V; Huerga C; Bullo F
    Br J Clin Pharmacol; 2022 Mar; 88(3):1063-1073. PubMed ID: 34374114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects.
    Hanes V; Chow V; Zhang N; Markus R
    Cancer Chemother Pharmacol; 2017 May; 79(5):881-888. PubMed ID: 28341959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing the pharmacokinetics, safety, and immunogenicity of HLX02 to US- and EU-approved trastuzumab in healthy Chinese male subjects: A Phase I, randomized, double-blind, parallel-group study.
    Zhou W; Wang M; Yu Y; Wang J; Wu Y; Yang G; Yu H; Li J; Zhou L; Zhang Q
    Expert Opin Biol Ther; 2023; 23(8):717-725. PubMed ID: 36843059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects.
    Pivot X; Curtit E; Lee YJ; Golor G; Gauliard A; Shin D; Kim Y; Kim H; Fuhr R
    Clin Ther; 2016 Jul; 38(7):1665-1673.e3. PubMed ID: 27368117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial.
    Morita J; Tanaka M; Nomoto M; Matsuki S; Tsuru T; Matsuguma K; Shiramoto M
    BioDrugs; 2016 Feb; 30(1):17-25. PubMed ID: 26691837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers.
    Wisman LA; De Cock EP; Reijers JA; Kamerling IM; Van Os SH; de Kam ML; Burggraaf J; Voortman G
    Clin Drug Investig; 2014 Dec; 34(12):887-94. PubMed ID: 25377592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
    Hillson J; Mant T; Rosano M; Huntenburg C; Alai-Safar M; Darne S; Palmer D; Pavlova BG; Doralt J; Reeve R; Goel N; Weilert D; Rhyne PW; Chance K; Caminis J; Roach J; Ganguly T
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects.
    Hanes V; Chow V; Pan Z; Markus R
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):899-905. PubMed ID: 30269275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
    Wynne C; Altendorfer M; Sonderegger I; Gheyle L; Ellis-Pegler R; Buschke S; Lang B; Assudani D; Athalye S; Czeloth N
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1361-1370. PubMed ID: 27813422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study.
    Schwabe C; Wynne C; Dyapa DR; Prajapati A; Dadke D
    Oncol Ther; 2024 Sep; 12(3):477-490. PubMed ID: 38972020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers.
    Shin D; Lee Y; Kim H; Körnicke T; Fuhr R
    J Clin Pharm Ther; 2017 Dec; 42(6):672-678. PubMed ID: 28675520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects.
    Lee HA; Jang H; Jeong D; Kim Y; Fuhr R
    Int J Clin Pharmacol Ther; 2022 Jun; 60(6):269-279. PubMed ID: 35348111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar.
    Wang Y; Liu Z; Deng Q; Su Z; Xue J; Zhao Y; Yang H
    Expert Opin Drug Metab Toxicol; 2023; 19(11):849-855. PubMed ID: 37526387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab.
    Yang C; Khwaja R; Tang P; Nixon N; King K; Lupichuk S
    Curr Oncol; 2022 Jun; 29(6):4224-4234. PubMed ID: 35735446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects.
    Zhang H; Li Q; Zhu X; Li C; Li X; Liu C; Hu Y; Chen G; Wei H; Wang J; Shen Z; Ding Y
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):615-623. PubMed ID: 30043208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus.
    Heise T; Donnelly C; Barve A; Aubonnet P
    Diabetes Obes Metab; 2020 Apr; 22(4):521-529. PubMed ID: 31724253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
    Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
    Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.